Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.

International journal of hematology

Volumn 99, Issue 2, 2014, Pages 141-153

  Fujisawa, Shin ^a   Nakamae, Hirohisa ^b   Ogura, Michinori ^b   Ishizawa, Ken ichi ^b   Taniwaki, Masafumi ^b   Utsunomiya, Atae ^b   Matsue, Kosei ^b   Takamatsu, Yasushi ^b   Usuki, Kensuke ^b   Tanimoto, Mitsune ^b   Ishida, Yoji ^b   Akiyama, Hideki ^b   Onishi, Shintaro ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; DASATINIB; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; FOLLOW UP; GENETICS; HUMAN; JAPAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; MYELOID LEUKEMIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; JAPAN; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL ANALYSIS; THIAZOLES; YOUNG ADULT;

EID: 84906929521     PISSN: None     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1470-1     Document Type: Article

References (0)